Inmed's neurodegenerative disease study presented at canadian neuroscience meeting

Vancouver, british columbia--(newsfile corp. - june 1, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that results from a neurodegenerative disease study was presented in a scientific poster at the canadian neuroscience meeting in montreal from may 28-31, 2023. the inmed sponsored research, entitled "cannabinoids modulate cytotoxicity and neuritogenesis in amyloid-beta-treated neuronal cells", demonstrated the ability of a specific rare cannabinoid ("pcbx") in inmed's 900 series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro, all considered to be important targets in the potential treatment of neurodegenerative diseases such as alzheimer's.
INM Ratings Summary
INM Quant Ranking